The relationship between the heart-type fatty acid binding protein levels, carotid intima media thickness and epicardial fat thickness in patients with obstructive sleep apnea syndrome

Azar, Cebrail; Abakay, Özlem; Azar, Sengül; Kermenli, Tayfun; Yüksel, Hatice

doi:10.5578/tt.68912

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Azar et al evaluated the association between EAT thickness and the levels of heart-type fatty acid binding protein (hFABP) in patients with obstructive sleep apnea syndrome (OSAS) (n = 99 OSAS patients compared with 50 control subjects). 62 hFABP levels in the OSAS group were significantly higher compared with the control group (2.65 ± 2.1 vs 1.62 ± 0.90 ng/mL; P = 0.002). EAT thickness in the OSAS and control group were 4.3 ± 1.79 and 5.3 ± 2.04 mm, respectively ( P = 0.019).…”

Section: Eat and Pat As Predictors Of Cvd Riskmentioning

confidence: 79%

Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?

Muzurović

Vujosevic

Mikhailidis

2021

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic and complex metabolic disorder and also an important cause of cardiovascular (CV) disease (CVD). Patients with type 2 DM (T2DM) and obesity show a greater propensity for visceral fat deposition (and excessive fat deposits elsewhere) and the link between adiposity and CVD risk is greater for visceral than for subcutaneous (SC) adipose tissue (AT). There is growing evidence that epicardial AT (EAT) and pericardial AT (PAT) play a role in the development of DM-related atherosclerosis, atrial fibrillation (AF), myocardial dysfunction, and heart failure (HF). In this review, we will highlight the importance of PAT and EAT in patients with DM. We also consider therapeutic interventions that could have a beneficial effect in terms of reducing the amount of AT and thus CV risk. EAT is biologically active and a likely determinant of CV morbidity and mortality in patients with DM, given its anatomical characteristics and proinflammatory secretory pattern. Consequently, modification of EAT/PAT may become a therapeutic target to reduce the CV burden. In patients with DM, a low calorie diet, exercise, antidiabetics and statins may change the quantity of EAT, PAT or both, alter the secretory pattern of EAT, improve the metabolic profile, and reduce inflammation. However, well-designed studies are needed to clearly define CV benefits and a therapeutic approach to EAT/PAT in patients with DM.

show abstract

Section: Eat and Pat As Predictors Of Cvd Riskmentioning

confidence: 79%